Table 1.
Sample 1 | CFUs/50 μL | ||||||
---|---|---|---|---|---|---|---|
10−1 | 10−2 | 10−3 | 10−4 | 10−5 | 10−6 | 10−7 | |
Model | UC 2 | UC | UC | UC | UC | 37 ± 6 | 37 ± 7 |
Model + Blank | UC | UC | UC | UC | UC | 60 ± 8 | 39 ± 6 |
Model + 2.0 μg/mL | UC | UC | UC | UC | 60 ± 6 | 35 ± 7 | 5 ± 2 |
Model + 4.0 μg/mL | UC | UC | UC | UC | 59 ± 12 | 31 ± 6 | 22 ± 7 |
Model + 8.0 μg/mL | UC | UC | UC | UC | 30 ± 5 | 23 ± 5 | 12 ± 3 |
Model + 16.0 μg/mL | UC | UC | UC | 25 ± 6 | 3 ± 1 | 3 ± 2 | 2 ± 2 |
Model + 32.0 μg/mL | UC | 37 ± 9 | 3 ± 2 | 0 | 0 | 0 | 0 |
1 Model, S. aureus mature biofilm without further incubation in 200 μL TSB and treatment of azalomycin F5a; Model + Blank, S. aureus mature biofilm further incubated in 200 μL TSB while no treatment of azalomycin F5a; Model + 2.0, 4.0, 8.0, 16.0 and 32.0 μg/mL, S. aureus mature biofilm further treated with azalomycin F5a at the concentration of 2.0, 4.0, 8.0, 16.0 and 32.0 μg/mL, respectively.2 UC, Uncounted as there were too many to count accurately.